Traws Pharma, Inc. (TRAW)
Automate Your Wheel Strategy on TRAW
With Tiblio's Option Bot, you can configure your own wheel strategy including TRAW - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol TRAW
- Rev/Share 0.0089
- Book/Share -1.2497
- PB -1.1443
- Debt/Equity 0.0
- CurrentRatio 2.1634
- ROIC -1.8545
- MktCap 7956963.0
- FreeCF/Share -1.177
- PFCF -0.2671
- PE -0.2174
- Debt/Assets 0.0
- DivYield 0
- ROE 5.0019
- Rating C+
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 4
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| No ratings available. | |||||||
News
Traws Pharma Announces Publication of Compelling Efficacy data in RDEB SCC Patients Treated with Legacy Oncology Drug Rigosertib
Published: June 03, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEWTOWN, Pa., June 03, 2025 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (NASDAQ: TRAW) (“Traws Pharma”, “Traws” or “the Company”), a clinical-stage biopharmaceutical company developing novel therapies to target critical threats to human health from respiratory viral diseases, today announced the publication of key clinical efficacy data for rigosertib, a legacy Traws Pharma oncology asset for which development and commercialization partners are being actively sought, in patients with RDEB SCC. The paper, published in the British Journal of Dermatology 1 , details the first clinical trial of any experimental cancer therapeutic in this rare and complicated monogenic disease. The results indicated …
Read More
Traws Pharma Regains Compliance with NASDAQ Equity Listing Rule
Published: February 28, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEWTOWN, Pa., Feb. 28, 2025 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (Nasdaq: TRAW) (“Traws” or “Traws Pharma”), a clinical stage biopharmaceutical company developing oral small molecules for the treatment of respiratory viral diseases, announced today that it has received confirmation from Nasdaq that Traws has regained compliance with the minimum stockholders' equity requirements of Nasdaq Listing Rule 5550(b)(1), which requires listed companies to maintain a minimum of $2.5 million in stockholders' equity. Accordingly, Traws common stock will continue to be listed and trade on The NASDAQ Capital Market under the symbol “TRAW”.
Read More
About Traws Pharma, Inc. (TRAW)
- IPO Date
- Website https://www.trawspharma.com
- Industry Biotechnology
- CEO Iain D. Dukes DPHIL,
- Employees 6